Company: IMNN
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0001641172-25-014324
Chunk: 47

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 47
---
 Warrants will expire three years from the effective date of Stockholder Approval.

A holder of the Pre-Funded Warrants and the Common Warrants may not exercise any portion of such holder’s Pre-Funded Warrants or Common Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding shares of common stock immediately after exercise, except that upon at least 61 days’ prior notice from the holder to the Company, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise. In the event of certain fundamental transactions, the holders of Common Warrants have the right to require the Company or a successor entity to purchase the Common Warrants from the holder for an amount of consideration equal to the Black Scholes Value (as defined in the Common Warrants) of the remaining unexercised portion of the Common Warrants concurrently with or within 30 days following the consummation of a fundamental transaction.

In connection with the Private Placement, we entered into a registration rights agreement (“Registration Rights Agreement”), dated as of May 23, 2025, with the investors, pursuant to which we agreed to prepare and file a registration statement with the SEC registering the resale of the Shares and the shares of common stock underlying the Pre-Funded Warrants and the Common Warrants no later than 15 days after the date of the Registration Rights Agreement (the “Registration Statement”).

H.C. Wainwright & Co., LLC (“Wainwright”) acted as our lead placement agent, and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent, in connection with the Private Placement, pursuant to the Engagement Letter dated as of May 22, 2025 (the “Engagement Letter”), between us and Wainwright. In addition, we issued to Wainwright, or its designees, warrants (the “Placement Agent Warrants” and together with the Common Warrants, the “Warrants”) to purchase up to an aggregate of 361,111 shares of common stock at an exercise price equal to $0.5625 per share (the “Placement Agent Warrant Shares” and together with the Common Warrant Shares, the “Warrant Shares”). The Placement Agent Warrants have substantially the same terms as the Common Warrants.

Nas